# A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

> **NCT04077099** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 231 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** REGN5093

## Key facts

- **NCT ID:** NCT04077099
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-07
- **Primary completion:** 2032-04-22
- **Final completion:** 2032-04-22
- **Target enrollment:** 231 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077099, "A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04077099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*